Jane Ryan - 20 Jan 2026 Form 4 Insider Report for Neuphoria Therapeutics Inc. (NEUP)

Role: Director
Signature: /s/ Elaine Wangsawidjaja, Attorney-in-Fact for Jane Ryan
Issuer symbol: NEUP
Transactions as of: 20 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 21 Jan 2026, 16:01:27 UTC
Previous filing: 18 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ryan Jane	Director	100 SUMMIT DRIVE, BURLINGTON	/s/ Elaine Wangsawidjaja, Attorney-in-Fact for Jane Ryan	21 Jan 2026	0002028936

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NEUP	Restricted Stock Units	Award	$0	+8,537	+122%	$0.000000	15,550	20 Jan 2026	Common Stock	8,537		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.1.
F2	The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy.
F3	Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest.